Monopar Therapeutics (MNPR) Competitors $35.86 +2.35 (+7.01%) Closing price 04:00 PM EasternExtended Trading$36.31 +0.45 (+1.25%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. MLYS, IMNM, ZYME, ATAI, URGN, OCS, ORIC, NUVB, SION, and NAGEShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Mineralys Therapeutics (MLYS), Immunome (IMNM), Zymeworks (ZYME), atai Life Sciences (ATAI), Urogen Pharma (URGN), Oculis (OCS), Oric Pharmaceuticals (ORIC), Nuvation Bio (NUVB), Sionna Therapeutics (SION), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Its Competitors Mineralys Therapeutics Immunome Zymeworks atai Life Sciences Urogen Pharma Oculis Oric Pharmaceuticals Nuvation Bio Sionna Therapeutics Niagen Bioscience Mineralys Therapeutics (NASDAQ:MLYS) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Do insiders & institutionals hold more shares of MLYS or MNPR? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 25.6% of Mineralys Therapeutics shares are owned by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts rate MLYS or MNPR? Mineralys Therapeutics currently has a consensus target price of $32.25, suggesting a potential upside of 128.24%. Monopar Therapeutics has a consensus target price of $60.00, suggesting a potential upside of 67.32%. Given Mineralys Therapeutics' higher probable upside, analysts plainly believe Mineralys Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is MLYS or MNPR more profitable? Monopar Therapeutics' return on equity of -45.72% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -74.35% -69.03% Monopar Therapeutics N/A -45.72%-42.76% Which has more volatility & risk, MLYS or MNPR? Mineralys Therapeutics has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Does the media favor MLYS or MNPR? In the previous week, Monopar Therapeutics had 1 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 9 mentions for Monopar Therapeutics and 8 mentions for Mineralys Therapeutics. Monopar Therapeutics' average media sentiment score of 0.89 beat Mineralys Therapeutics' score of 0.84 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, MLYS or MNPR? Monopar Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.79Monopar TherapeuticsN/AN/A-$15.59M-$3.33-10.77 SummaryMonopar Therapeutics beats Mineralys Therapeutics on 9 of the 13 factors compared between the two stocks. Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$219.46M$3.08B$5.58B$9.81BDividend YieldN/A2.27%4.60%4.11%P/E Ratio-10.7720.5630.2825.72Price / SalesN/A191.86388.3180.18Price / CashN/A42.0537.7558.93Price / Book3.987.598.456.01Net Income-$15.59M-$54.65M$3.25B$265.06M7 Day Performance-10.57%5.43%4.05%2.80%1 Month Performance-18.00%6.75%4.32%1.68%1 Year Performance1,486.73%31.59%36.25%29.59% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics3.0516 of 5 stars$35.86+7.0%$60.00+67.3%+1,273.4%$219.46MN/A-10.7710News CoverageEarnings ReportAnalyst ForecastMLYSMineralys Therapeutics3.0158 of 5 stars$13.19+1.5%$32.25+144.5%+14.6%$847.28MN/A-3.5428News CoverageEarnings ReportAnalyst ForecastIMNMImmunome1.7498 of 5 stars$9.66-0.3%$23.14+139.6%-26.0%$843.47M$9.04M-3.1440Analyst RevisionZYMEZymeworks0.2585 of 5 stars$12.44+3.5%N/AN/A$837.60M$76.30M-12.82460Earnings ReportATAIatai Life Sciences2.8412 of 5 stars$3.96-4.1%$11.25+184.1%+232.0%$827.39M$310K-4.3580Earnings ReportGap UpURGNUrogen Pharma4.5617 of 5 stars$18.24+2.8%$31.43+72.3%+34.4%$820.96M$90.40M-5.49200Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionOCSOculis3.046 of 5 stars$17.97-1.3%$35.33+96.6%+57.2%$795.09M$780K-6.812Short Interest ↓ORICOric Pharmaceuticals4.6874 of 5 stars$9.20-0.4%$18.57+101.9%+11.2%$787.47MN/A-4.9280News CoverageEarnings ReportAnalyst ForecastShort Interest ↓NUVBNuvation Bio2.3586 of 5 stars$2.24-2.8%$7.33+228.1%-5.5%$782.60M$7.87M-3.5560Earnings ReportSIONSionna Therapeutics2.1175 of 5 stars$20.03+13.4%$38.50+92.2%N/A$779.68MN/A0.0035Earnings ReportNAGENiagen Bioscience1.3661 of 5 stars$9.82+0.9%$13.42+36.7%N/A$776M$99.60M46.76120News CoverageAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Immunome Alternatives Zymeworks Alternatives atai Life Sciences Alternatives Urogen Pharma Alternatives Oculis Alternatives Oric Pharmaceuticals Alternatives Nuvation Bio Alternatives Sionna Therapeutics Alternatives Niagen Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access